Background: Pregnant patients with cancer are increasingly treated with anticancer drugs, although the specific impact of pregnancy-induced physiological changes on the pharmacokinetics (PK) of anticancer drugs and associated implications for optimal dose regimens remains unclear. Our objectives were to quantify changes in PK during pregnancy for four frequently used anticancer agents doxorubicin, epirubicin, docetaxel and paclitaxel, and to determine associated necessary dose adjustments.
even more complex, as the incidence of malignancies necessitating chemotherapy during pregnancy is very low and the participation in PK studies specifically is relatively burdensome for patients. Because the quantification of effects of pregnancy on PK parameters in small groups of patients can be challenging, appropriate methods of data analysis are critical [7] [8] [9] .
Initial results of the first systematic study exploring the PK of several frequently used anticancer agents have been reported by van Calsteren et al. [10] . The current work is based on that study, but has been extended with the addition of data of a substantial number of pregnant patients. Furthermore, we included much larger cohorts of nonpregnant patients as controls, to further support estimation of gestational effects of PK during pregnancy. Finally, in contrast to the initial report by van Calsteren et al. [10] , we have used a model-based nonlinear mixed effect (NLME) modeling approach that allowed efficient analysis of all available data and translation of identified gestational effects to dose regimen adjustments.
The objectives of this analysis were to quantify gestational effects on PK parameters of doxorubicin, epirubicin, docetaxel and paclitaxel, and to propose dose regimen adjustments based on identified gestational effects. methods study data PK data for doxorubicin, epirubicin, paclitaxel and docetaxel were included in this analysis from both pregnant and nonpregnant patients. An overview of included data and patients is shown in Table 1 .
nonpregnant patients. For doxorubicin, data were included for 59 nonpregnant patients with breast cancer [11] . For epirubicin, data from 57 nonpregnant patients with solid tumors were included [12] . PK data in nonpregnant patients for docetaxel (n = 32) was obtained from a study comparing i.v. docetaxel with orally administered docetaxel [13] Finally, we included paclitaxel PK data from 105 nonpregnant patients with ovarian cancer [14] . pregnant patients. For doxorubicin, epirubicin, docetaxel, paclitaxel, we included 14, 10, 3 and 5 pregnant patients, respectively. Informative concentration-time curves were obtained, with 8-12 samples per patient. For doxorubicin, patients were included between 14.7 and 34.3 gestational weeks (GW); for epirubcin, this number was between 19 and 36.9 GW; for docetaxel, between 32 and 36.1 GW; and for paclitaxel between 17 and 29.3 GW. For some patients, postpartum (PP) PK profiles were available.
ethics. All studies were approved by an Institutional Review Board or Independent Ethics Committee and conducted in accordance with ICH guidelines and the Declaration of Helsinki.
software All PK models were constructed using NONMEM (version 7.1) employing the first-order conditional estimation method with interaction. Postprocessing of data was conducted using R (version 2.15).
pharmacokinetics
We systematically developed compartmental NLME models to describe the PK for the four drugs that were included. Model properties, such as the number of compartments, variance structures for between-subject, betweenoccasion and residual random effects, and inclusion of covariate effects, were based on the following model selection criteria: plausible parameter Between-subject variability around parameters was modeled according to a log-normal distribution. The residual error was modeled according to a proportional relationship.
Gestational effects were included in the model if they could be estimated with adequate precision (RSE <30%).
Relationships between gestational age (GA) on clearance (CL) and volumes of distribution (V 1 , V 2 , V 3 ) were evaluated graphically and were univariately tested in each base PK model. Here, V 1 refers to the central distribution volume accounting for fast drug distribution, whereas V 2 and V 3 represent peripheral tissue drug distribution volumes accounting for slower distribution processes. Because of changes in body composition during pregnancy, distribution volumes may change. Both (continuous) linear slopeintercept models using GA were considered, as well as implementations using discrete gestational effects, including PP changes.
Evaluation of the final model was carried out using the visual predictive check (VPC), in which we simulated 1000 datasets, stratifying between pregnant and nonpregnant patients.
simulations
For each drug, deterministic simulations from the final model were carried out to evaluate the effect of pregnancy on concentration-time profiles and, subsequently, to determine the magnitude of dose regimen adjustments required to match nonpregnant exposure levels [in terms of area under the concentration-time curve (AUC)], while not exceeding the maximum concentration observed in nonpregnant patients. In addition, for paclitaxel, the dose was optimized with respect to a time above the 0.1 μM paclitaxel concentration threshold (85.39 ng/ml), which has been shown to correlate to treatment efficacy and toxicity [15] . Dose regimens were optimized taking into account both dose and infusion duration. The algorithm for the multivariate dose regimen optimization is described in more detail in the supplementary material, available at Annals of Oncology online.
results pharmacokinetics
Linear three-compartmental models were identified for all drugs. Parameter estimates of the final models are provided in Table 2 .
For all available drugs, only a limited number of pregnant patients was available, and chemotherapy was only administered between 14.7 and 36.9 weeks of gestation. Therefore, we were not able to estimate continuous covariate relationships (linear or Emax) between GA and structural PK parameters. In addition, we were not able to separately estimate parameters for the second and third trimester, although, in both trimester, a change from the nonpregnant values was apparent. Therefore, a single discrete pregnancy effect was estimated.
doxorubicin. Model parameters of doxorubicin were estimated with RSE <47% for the structural model parameters and RSE Figure S1 , available at Annals of Oncology online, and indicated adequate description of both the pregnant and nonpregnant concentration-time profiles.
simulations Using the final parameters estimated for each drug (Table 2) , deterministic simulations were carried out using the typical (unadjusted) dose regimens for both nonpregnant and pregnant patients. In addition, dose regimens were optimized by adapting dose amounts and infusion durations to match nonpregnant exposure in terms of AUC, and in case of paclitaxel using a time >0.1 μM threshold concentration. The typical concentrationtime profiles in each of these three scenarios are depicted in supplementary Figure S2 , available at Annals of Oncology online. The unadjusted and optimized dose regimens and associated PK metrics in pregnant and nonpregnant patients are provided in Table 3 and are graphically depicted in Figure 1 .
The typical AUC of doxorubicin was 5.2% reduced in pregnant patients. An adjustment in dose amount of 5.5% and an increase in infusion duration of 4.2% were predicted to lead to an exposure equal to nonpregnant patients, without exceeding the typical predicted peak concentration in nonpregnant patients.
For epirubicin, the typical AUC was 8.2% reduced in pregnant patients. In order to obtain similar exposure as observed in nonpregnant patients, dose amounts need to be increased by 8%, and the infusion duration was negligible (increased of 0.9%).
In case of docetaxel, the typical AUC was 14.5% reduced in pregnant patients. Increase of the dose amount by 16·9%, and an increase of the infusion duration by 2.2% is required to match exposure to nonpregnant patients. Finally, for paclitaxel, the typical AUC during pregnancy was decreased by 27.4%, while the time above the threshold was decreased with 10·9%. When adapting the dose to obtain an AUC similar to adults, dose needs to be increased by 37.8% whereas infusion duration needs to be adjusted by −21.4%. This adjustment, however, would lead to a further decreased time above the 0.1 μM threshold. When adjusting dose to match the nonpregnant time above 0.1 μM, the dose needs to be reduced by −35.5% while the infusion duration needs to be increased with 10.6%, resulting in a decrease in AUC (−54%).
discussion
Based on the identified effects of pregnancy on PK parameters, a consistent decrease in exposure during pregnancy was apparent for all drugs studied. The predicted AUCs between nonpregnant and pregnant patients were compared with identify the impact of the identified changes in PK parameters (Table 3) . Doxorubicin, epirubicin, docetaxel and paclitaxel showed typical decreases in AUC of 5.3%, 8.2%, 14.5% and 27.4%, respectively.
anthracyclines
For doxorubicin, limited changes in distributional volumes (<1.32-fold increase) were identified. Change in CL could probably not be identified due to the large interindividual variations observed (<69.9 CV%), i.e. a much higher number of pregnant subjects would be needed to identify such an effect. Nonetheless, if an effect on CL is present, this is likely to be of limited magnitude.
In case of epirubicin, a 1.1-fold increase in CL was identified, thereby supporting the supposed limited changes for the structurally similar doxorubicin. More substantial changes for distribution volumes were observed for epirubicin (<2.08-fold increase).
However, these effects mainly related to the initial distribution phase and could not be identified for the terminal elimination phase which would have influenced exposure most strongly.
Doxorubicin and epirubicin are metabolized by CYP3A4 whereas epirubicin is also glucuronidated by UGTB7 [16] . For both CYP3A4 and UGTB7, increased activity has been reported during pregnancy [3] . With respect to gestational changes in albumin, a limited effect was expected as both drugs are only moderately protein bound (50%-85%). Furthermore, both doxorubicin and epirubicin are excreted renally only to limited extent, thereby also limiting the influence of increased renal function during pregnancy [17] .
taxanes
For docetaxel, we identified a 1.19-fold-change in CL (RSE 7%), and in addition limited changes (<1.37-fold increases) in primary volumes of distribution. The change in CL for docetaxel should be interpreted with caution given the limited number of patients included for this drug (n = 4).
In case of paclitaxel, a 1.92-fold-change (RSE 41%) in CL, and 2.57-to 4.21-fold increase in volumes of distribution were estimated.
Docetaxel and paclitaxel are both metabolized by CYP3A4, and in addition paclitaxel is also metabolized by CYP2C8 [18] , for which gestational changes are unknown. Unlike the studies of anthracyclines, docetaxel and paclitaxel are highly protein bound [19] , increasing the potential impact of gestational changes in albumin [20] .
clinical implications
In some cases, clinicians may intuitively favor to implement initial dose reductions as precautionary measure in pregnant patients. However, the current analysis showed a consistent decrease in exposure for all four drugs evaluated. Hence, a priori dose reductions during pregnancy are not recommended. The magnitude of dose adjustments identified for doxorubicin and epirubicin was limited and may not be clinically relevant. For the taxanes, however, changes in PK were larger and in this case suggested dose regimen adjustments could be considered.
For other drugs, it has been well established that changes in PK are generally most pronounced in the third trimester [3] . Therefore, the combined second and third trimester pregnancy effect estimated in the current analysis is likely to be underestimated to a certain extent for the third trimester, while overestimated in the second trimester. Given this rationale, and the acceptable estimation precision of gestational effects, a dose adjustment in the third trimester only would thus still remain a conservative dose adjustment. Nonetheless, more pregnant patients should be studied in the future to gain further confidence in dosing guidelines in this special patient population.
In addition, previously it was shown that pregnant patients with breast cancer do not have different clinical outcomes (i.e. survival) compared with nonpregnant breast cancer patients [21, 22] . This may appear somewhat contrasting with our finding of decreased drug exposure identified for at least the taxanes, which should potentially be associated with decreased efficacy. However, the PK of the taxanes is associated with significant interindividual variability which may be as large as 52. CV% on CL for paclitaxel, as identified in the current analysis, which potentially explains why the effect of a small to moderate change in PK on survival, will require very large sample sizes in order to be identified.
nonlinear mixed effect modeling approach
The applied NLME platform allowed an efficient statistical framework to maximize the informativeness of inference derived from this longitudinal PK dataset, taking into account different levels of variability and thereby ultimately increasing the power and accuracy for estimating gestational effects. Moreover, the applied NLME approach allowed integration of nonpregnant PK data, supporting overall estimation of gestational effects on PK, which is not possible in the context of conventional noncompartmental analysis. Finally, NLME approaches can also be applied for simulations to evaluate alternative treatment strategies [23, 24] .
limitations
Only a fixed pregnancy effect could be estimated, i.e. a continuous effect of pregnancy on PK parameters could not be identified. This was most likely related to the relatively small number of patients available across different gestational periods, and large interindividual variation in PK parameters. Nonetheless, a relationship with gestational time could be expected based on the known time-dependent changes of various physiological factors that may influence PK. Although some data in PP patients were available, we did not identify any PP effects on PK, because this samples were mostly taken after a longer period of delivery, i.e. the study design did not support estimation of such effects. Therefore, occasions with PP PK data were considered as a nonpregnant state, and were analyzed as such.
With increasing use of anticancer agents during pregnancy, an increasing need for guidance on optimal drug treatment of anticancer agents in pregnant patients exists. The current study still contains a limited number of patients due to the low incidence of cancer during pregnancy. Nonetheless, the patients included in the current analyses were enrolled over a substantial time period in the context of a multicenter international clinical trial setting. Even though the sample size was limited, together with the included dataset of nonpregnant patients, and the NLME approach used, this analysis provided insight into the extent of changes in PK and its impact on dose adjustments.
conclusions
Clinicians should be aware of a decrease in drug exposure during pregnancy and should not a priori reduce dose. The decrease in exposure was most apparent for docetaxel and paclitaxel which is supported by known physiological changes during pregnancy. The suggested dose adaptations should only be implemented after conduct of further confirmatory studies of the PK during pregnancy. references
